Covered recipient · General Payments record
SHALINI GUPTA
Allopathic & Osteopathic Physicians Dermatology
General Payments · PY2018–2024
$4,132.05
- Reported across 26 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $372.26 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| UCB, Inc. | $74.03 | 4 |
| Lilly USA, LLC | $69.66 | 3 |
| MERZ NORTH AMERICA, INC. | $54.77 | 2 |
| ABBVIE INC. | $48.52 | 2 |
| Verrica Pharmaceuticals Inc. | $45.23 | 2 |
| ORGANOGENESIS INC. | $25.71 | 1 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $20.56 | 1 |
| Regeneron Healthcare Solutions, Inc. | $19.96 | 1 |
| Amgen Inc. | $13.82 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $28.10 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103853775 | CMS |
| ABBVIE INC. | $20.42 | 12/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103853777 | CMS |
| Amgen Inc. | $13.82 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117569591 | CMS |
| Lilly USA, LLC | $22.80 | 01/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135422689 | CMS |
| Lilly USA, LLC | $23.68 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135422691 | CMS |
| Lilly USA, LLC | $23.18 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135424313 | CMS |
| MERZ NORTH AMERICA, INC. | $32.08 | 07/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146375030 | CMS |
| MERZ NORTH AMERICA, INC. | $22.69 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146375032 | CMS |
| Organogenesis Inc. | $25.71 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145430023 | CMS |
| Regeneron Healthcare Solutions, Inc. | $19.96 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114062051 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $20.56 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152201461 | CMS |
| UCB, Inc. | $18.33 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143030222 | CMS |
| UCB, Inc. | $15.85 | 03/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143030224 | CMS |
| UCB, Inc. | $14.41 | 08/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143030226 | CMS |
| UCB, Inc. | $25.44 | 11/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143030228 | CMS |
| Verrica Pharmaceuticals Inc. | $16.11 | 04/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118381462 | CMS |
| Verrica Pharmaceuticals Inc. | $29.12 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118381464 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.